RECOVERY & TISSUE REPAIR / FAQ
Questions readers bring to TB-500, KPV and KLOW
Direct, citation-anchored answers drawn from the peer-reviewed and preclinical literature.
What is TB-500?
TB-500 is a synthetic, seven-amino-acid peptide (Ac-LKKTETQ) corresponding to a short fragment of thymosin beta-4, a naturally occurring protein involved in cell migration and tissue repair. Most of the encouraging efficacy data associated with the name actually come from studies of the full-length parent protein rather than the short fragment itself [1][3]. It has no approved human or veterinary medical use and is sold only as a research chemical.
What does TB-500 stand for and what does TB stand for in TB-500?
"TB" refers to thymosin beta — the peptide family TB-500 is derived from — and "500" is a commercial designation rather than a standardized scientific number tied to molecular weight or sequence length. In scientific and anti-doping literature, the compound is more precisely identified as Ac-LKKTETQ or as the thymosin beta-4(17-23) fragment [1].
What is TB-500 used for in research?
In research settings, thymosin beta-4 and its TB-500 fragment are studied for their proposed role in cell migration, new blood-vessel formation (angiogenesis), reduced scar-tissue formation, and anti-inflammatory signaling after injury [3]. Studies span animal models of stroke [2], wound healing, and cardiac and corneal repair [3], plus one human Phase 1 intravenous safety study using the full-length protein [4]. None of this constitutes an approved human therapeutic use.
Does TB-500 work for muscle tears and recovery from exercise?
There is no controlled human trial testing TB-500 (the fragment) for muscle-tear or exercise-recovery outcomes. A 2026 review of unapproved peptides used for musculoskeletal injuries, including TB-500, found favorable outcomes in animal models but concluded that human safety and efficacy data remain scarce for this class of compound [1]. Community reports describing faster-feeling recovery from tendon and muscle injuries are widespread but are anecdotal, not controlled clinical findings.
What is KPV peptide?
KPV is a three-amino-acid peptide (lysine-proline-valine) that represents the C-terminal fragment of alpha-melanocyte-stimulating hormone (alpha-MSH). It retains the parent hormone's anti-inflammatory activity while lacking its effect on pigmentation [10]. KPV has no published human clinical trials; its research base is preclinical, mainly mouse models of colitis [8][9].
What does KPV peptide do?
In laboratory studies, KPV is taken up by intestinal cells through the PepT1 transporter, which is more active in inflamed tissue, and it suppresses NF-κB and MAP-kinase inflammatory signaling while reducing pro-inflammatory cytokine secretion [8]. In mouse colitis models this translates to reduced inflammatory infiltrate, lower tissue-level immune-cell activity, and faster recovery of body weight [9]. It has also accelerated corneal wound healing in a rabbit model through a nitric-oxide-linked mechanism [11].
What is KPV peptide used for?
KPV is studied experimentally as an anti-inflammatory agent, primarily in the context of intestinal inflammation (colitis) [6][7][8][9], and secondarily in corneal wound healing [11]. It is sold by chemical suppliers strictly for laboratory research use and has no approved drug or dietary-supplement status in any major jurisdiction.
What is KPV peptide good for?
Based on the published literature, KPV's most consistent research signal is anti-inflammatory activity at mucosal surfaces, particularly the gut lining, where its uptake mechanism appears to concentrate it in inflamed tissue [8]. Reviewers describing the broader family of alpha-MSH-derived tripeptides note protective effects across a range of inflammatory animal models — fever, dermatitis, vasculitis, fibrosis, ocular, gastrointestinal, brain, airway and arthritic models [10] — but this remains preclinical evidence, not a demonstrated human benefit.
What is KLOW peptide?
KLOW is a research-vial blend combining four separate peptides — KPV, GHK-Cu, BPC-157 and TB-500 — co-dissolved together, most commonly reported at an 80 mg total vial (GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg). It is not a single molecule, and the four-peptide combination has never been tested together in any controlled study.
What is KLOW peptide used for?
KLOW's rationale draws on each component's individual research: KPV's anti-inflammatory activity, GHK-Cu's matrix-synthesis and gene-expression effects [14][15], BPC-157's proposed angiogenic signaling [13], and TB-500's proposed role in cell migration [1]. Because the combination itself is untested, any use-case claim for KLOW as a blend is an extrapolation from single-component data rather than direct evidence.
Where do you inject KLOW peptide?
This site does not provide injection guidance, site selection, or administration instructions for any compound. KLOW is sold strictly for laboratory research use, not for human administration, and this page is not a substitute for that fact. Readers looking for handling or administration information should be aware that no regulatory body has evaluated KLOW, or any of its four components in combination, for human use.
How much KLOW peptide per day?
This site does not recommend a dose for KLOW or for any peptide it covers. No controlled study has established a dose for the four-peptide combination, and no human trial of the blend exists to derive one from. Where this site cites a dose, it is always the dose used in a specific animal or human study — for example, the 42-1,260 mg intravenous doses in the thymosin beta-4 Phase 1 trial [4] or the up-to-20 mg intravenous BPC-157 pilot [13] — never a suggestion for a person to follow.